166 related articles for article (PubMed ID: 14974858)
1. Assessment of the protective effects of amifostine against cisplatin-induced toxicity.
Hussain AE; Blakley BW; Nicolas M; Balderston J
J Otolaryngol; 2003 Oct; 32(5):294-7. PubMed ID: 14974858
[TBL] [Abstract][Full Text] [Related]
2. [Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy].
Hyppolito MA; de Oliveira AA; Lessa RM; Rossato M
Braz J Otorhinolaryngol; 2005; 71(3):268-73. PubMed ID: 16446928
[TBL] [Abstract][Full Text] [Related]
3. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Church MW; Blakley BW; Burgio DL; Gupta AK
J Assoc Res Otolaryngol; 2004 Sep; 5(3):227-37. PubMed ID: 15185124
[TBL] [Abstract][Full Text] [Related]
4. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
5. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
6. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
7. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity.
Church MW; Kaltenbach JA; Blakley BW; Burgio DL
Hear Res; 1995 Jun; 86(1-2):195-203. PubMed ID: 8567417
[TBL] [Abstract][Full Text] [Related]
8. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
9. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
Duval M; Daniel SJ
J Otolaryngol Head Neck Surg; 2012 Oct; 41(5):309-15. PubMed ID: 23092832
[TBL] [Abstract][Full Text] [Related]
11. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
13. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
[TBL] [Abstract][Full Text] [Related]
14. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
15. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
16. Quantification of sodium thiosulphate protection on cisplatin-induced toxicities.
Leitao DJ; Blakley BW
J Otolaryngol; 2003 Jun; 32(3):146-50. PubMed ID: 12921131
[TBL] [Abstract][Full Text] [Related]
17. End points for cisplatin ototoxicity.
Qureshy K; Blakley B; Alsaleh S; Quddusi T; Berard S
J Otolaryngol Head Neck Surg; 2011 Feb; 40 Suppl 1():S45-8. PubMed ID: 21453661
[TBL] [Abstract][Full Text] [Related]
18. Mitochondria-Targeted Antioxidant Mitoquinone Reduces Cisplatin-Induced Ototoxicity in Guinea Pigs.
Tate AD; Antonelli PJ; Hannabass KR; Dirain CO
Otolaryngol Head Neck Surg; 2017 Mar; 156(3):543-548. PubMed ID: 28248600
[TBL] [Abstract][Full Text] [Related]
19. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
20. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]